One research study used generative AI to design a potent cancer treatment, while another found the technology gave dangerous advice.
On the one hand, UK-based biotech startup Etcembly just announced that it was able to use generative AI to design a novel immunotherapy that targets hard-to-treat cancers. Etcembly’s new therapeutic, called ETC-101, is a bispecific T cell engager, which means it targets a protein found in many cancers and not healthy tissue.
